Compare Open Text Corporation (OTEX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Tango Therapeutics Inc. — how do they compare? Open Text Corporation trades at $24.96 (market cap $6.02B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Open Text Corporation is the larger of the two by market cap, and Open Text Corporation pays a 4.49% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 24 Days and Tango Therapeutics Inc. for 0 Days on average.
| OTEX | TNGX | |
|---|---|---|
Market Cap | $6.02B | $3.75B |
Volume | 1,820,095 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $39.69 | $32.90 |
52-Week Low | $20.01 | $7.50 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $11.03B | $2.77B |
Dividend Yield | 4.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $24.95, up 3.18% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 9.67, robust 73.74% gross margins, and consistent earnings beats in recent quarters. Recent debt restructuring activities and strategic AI partnerships with Cohere highlight management's focus on growth optimization and technological advancement.
The outlook remains positive with a consensus price target of $28.30 offering 13% upside potential. Key risks include high debt levels and competitive pressures in the enterprise software sector. Analyst sentiment leans bullish with 42% buy ratings, though the stock faces near-term resistance at the $25 level.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
